Adverse events138

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 138

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Covid-19	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	7	31	7
other	Covid-19	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Cystitis	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	3	31	5
other	Cystitis	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Rash Pustular	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	2	31	2
other	Rash Pustular	Infections and infestations	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Pyogenic Granuloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	2	31	2
other	Pyogenic Granuloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Neutropenia	Blood and lymphatic system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	2	31	2
other	Neutropenia	Blood and lymphatic system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Thrombocytopenia	Blood and lymphatic system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	7	31	7
other	Thrombocytopenia	Blood and lymphatic system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Hypothyroidism	Endocrine disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	2	31	2
other	Hypothyroidism	Endocrine disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Decreased Appetite	Metabolism and nutrition disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	9	31	12
other	Decreased Appetite	Metabolism and nutrition disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Delirium	Psychiatric disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	2	31	2
other	Delirium	Psychiatric disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0
other	Dizziness	Nervous system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab	3	31	4
other	Dizziness	Nervous system disorders	Tusamitamab Ravtansine 100 mg/m^2 + Ramucirumab + Pembrolizumab		0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04394624/events

API reference For AI assistants

Adverse events138

Sources 3

Read this list from software.